Clinicians often assume that patients vaccinated for hepatitis B virus (HBV) have immunity. We report three cases of acute HBV infection in HBV-vaccinated HIV patients. These cases illustrate that patients at an elevated risk of HBV exposure presenting with acute hepatitis should be tested for HBV infection regardless of previous vaccination status.
Since the HBV vaccine was introduced in 1981, universal immunization programs have been adopted by many countries. Immunization follow-up studies on healthy immune-competent individuals have demonstrated greater than 95% serological HBV immunogenicity 10 year's post vaccination. 3 In individuals whose immune system has been compromised by the presence of HIV, HBV vaccine response rates are low (23.8-56% in adults and 35-45% in children). 4 Non-response is in part dependent on CD4 cell count. Only 33% of patients with CD4 counts between 200 and 500 cells/uL reach a protective level of antibody response to HBV (defined as anti-HBs titer higher than 10 IU/L) in comparison with 87.5% of patients with CD4 cell counts higher than 500 cells/uL. 4 In HIV-infected patients, HBsAb titres have also been found to diminish rapidly compared to non-infected individuals, 40% loss at 1 year as opposed to 5% loss in patients without HIV. The lower immune response to HBV vaccination, as well as the rapid loss of anti-HB surface antibodies (anti-HBs) in many HIV patients, suggests that this population may be at an increased risk of contracting HBV even when vaccinated. In this high-risk population, immediate HBV testing is indicated upon the development of acute hepatitis despite previous HBV vaccinations. Here we report three cases of acute HBV infection in HIV-positive patients previously vaccinated for HBV.
Methods
All cases were retrieved from the Toronto General Hospital Immunodeficiency Unit. Written consent was obtained from the patients. Acute HBV infection was diagnosed by seroconversion for hepatitis B surface antigen (HBsAg) and the absence of IgG antihepatitis B core antibodies (HBc) prior to HBsAg seroconversion. Acute HBV infection was confirmed through retrospective testing for HBV serology in sera that were collected and stored whenever HIV viral load testing was performed. We do not believe that HBsAg mutations influence our findings, since all three cases had viral load 9.08xE9 IU/mL and his CD4 count was 420 cells/µL. He was started on HIV therapy with HBV coverage (lamivudinetenfovir-lopinavir) in May 2007 in an attempt to clear the acute HBV infection and prevent chronic HBV infection. He subsequently developed markers suggesting clearance of HBV infection in May 2008: HBsAg negative, Anti-HBs positive, and an undetectable HBV DNA level (i.e., less than 12 IU/mL).
Discussion
We reported on three cases of acute HBV in HIV-infected persons who were previously vaccinated for HBV. The reasons for a lack of HBV immune protection differ among the presented cases. In two of these cases, however, the diagnosis of acute HBV infection was initially not considered due to the patient's history of HBV vaccination. Table 1 provides the case timeline for available vaccination and serological HBV-related test records for the three patients.
detectable HBsAg by commercial assays and they were all negative for the common drug-selected mutations in HBV polymerase (INNO-LiPA v2 line probe assay, Innogenetics, Belgium). C a n a d i a n J o u r n a l o f G e n e r a l I n t e r n a l M e d i c i n e
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V o l u m e 1 1 , I s s u e 4 , 2 0 1 6 previous HBV exposure by testing stored sera collected before HBV vaccination. The patient lost protective HBV immunity within 6 months post initial immunity confirmation. This is consistent with reported accelerated loss of HBsAb in the presence of HIV and may have contributed to the patient's vulnerability to HBV. In summary, we presented three cases of acute HBV in HIV-positive patients previously vaccinated for HBV. HBV testing and diagnosis in two of these patients was impeded by their history of HBV vaccination, resulting in a delay in targeted management. In persons continuously exposed to HBV, breakthrough infections can occur despite appropriate vaccination and even with evidence of immunity. Testing for HBV upon presentation with acute hepatitis should, therefore, be performed in at-risk populations, regardless of prior HBV vaccination status.
In the case of Patients 1 and 2, these patients failed to mount detectable anti-HBs antibodies despite repeated exposure to HBV antigen through vaccinations (3 complete vaccination rounds for Patient 1 and 1 round for Patient 2). HIV has been known to reduce the efficacy of HBV immunization. 4 This may have played a role in the lack of HBV protection demonstrated by Patient 2. This patient was diagnosed as HIV-positive prior to his HBV vaccination sequence. CD4 levels at the time of his vaccination were not measured, so it is unknown if this factor may have affected the patient's ability to develop HBV immunity. Patient 1's first HBV vaccination series was performed prior to acquisition of HIV, pointing to a reason for vaccine non-responsiveness other than HIV status. This patient was under age 49 and a cigarette smoker at the time, both factors are associated with reduced HBV vaccine efficacy.
6,7 While we did not carry out any genetic analyses in our patients, several genetic determinants have also been associated with lack of HBV vaccine response, namely presence of the HLA-DRB1*0701, DRB1*03, and B*15 alleles, and absence of the HLA-A*02 and DRB1*08 alleles. 8, 9 HBV genotype can also play a role in vaccination responsiveness. Acute hepatitis was previously observed in a patient with genotype F HBV, despite adequate anti-HBs titers. 10 Several amino acid substitutions exist in the 'a' determinant region and in the HBsAg of genotype F HBV which likely diminishes the protective effect of vaccine-induced anti-HBs antibodies against this variant.
10
Patient 3 contracted HBV despite having initially protective levels of anti-HBs. This has been reported only twice before. In a randomized control trial for the Merck 20µg HBV vaccine among homosexual men, 1.5% of vaccinated patients developed acute hepatitis B during their 15-month follow-up period. 11 One of the infected patients demonstrated protective HBsAb titer prior to his infection. It was subsequently discovered that a large proportion of participants in this trial were infected with HIV, thus coinfection may have played a role in vaccination failure. Unfortunately, prior HBV exposure was not evaluated in the trial and the possibility of chronic HBV reactivation cannot be discounted. In a 15-year prospective cohort study of a high-risk population ("Alaskan Native persons") vaccinated for HBV, 2.1% of patients who had shown protective serum HBsAb titer post vaccination eventually developed serological evidence of acute HBV infection. 12 This population was confirmed to be serologically negative for HBV prior to vaccination. These findings demonstrate that breakthrough HBV infections can occur in both healthy and immune-compromised individuals despite initial immunity. For Patient 3, we were able to exclude
